CAMBRIDGE, Mass., Feb. 02, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that the Company will present at the following investor conferences in February:
  • Leerink Partners Global Healthcare Conference (fireside chat format) on Wednesday, February 15, 2017 at 10:30 a.m. ET in New York City; and,
  • RBC Capital Markets Global Healthcare Conference (fireside chat format) on Thursday, February 23, 2017 at 8:30 a.m. ET in New York City.

Replays of the webcasts of the presentations can be accessed at the investor section of http://www.epizyme.com.

About Epizyme, Inc. Epizyme, Inc. is a clinical-stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients. Epizyme has built a proprietary product platform that the Company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing). By focusing on the genetic drivers of cancers, Epizyme's targeted science seeks to match the right medicines with the right patients. For more information, visit  www.epizyme.com.

Contact: Monique Allaire, THRUST IR617.895.9511monique@thrustir.com

Primary Logo